Browse the evidence

GLP-1RA therapy was associated with a lower risk of all-cause mortality in nondiabetic patients with PAD (HR: 0.40; 95% CI: 0.35–0.46; p < 0.001).

GLP-1RAs may help reduce overall mortality in patients with PAD who do not have diabetes.

GLP-1RA therapy was associated with a lower risk of major adverse limb events (MALE) in nondiabetic patients with PAD (HR: 0.22; 95% CI: 0.17–0.28; p < 0.001).

GLP-1RAs may reduce the risk of serious limb complications in patients with PAD who do not have diabetes.

There may be a potential causal relationship between tirzepatide and vitreous hemorrhage in nondiabetic patients.

Caution is advised when prescribing tirzepatide, especially in nondiabetic patients.

GIP and GLP-1 may modify glucagon secretion, impacting cardiac substrate utilization.

Understanding the role of GIP and GLP-1 in glucagon secretion can help tailor treatments for cardiac health in T2D.

Perturbations in cardiac energy metabolism are a major contributor to diabetes-related cardiovascular disease.

Addressing cardiac energy metabolism may be crucial in managing cardiovascular disease in T2D patients.

MPDA@TZP increased the retention time of TZP in the iWAT of mice and had a more dramatic effect on weight loss and improvement in plasma lipid profiles compared to TZP alone in DIO mice.

Encapsulating tirzepatide may enhance its effectiveness for weight loss in specific adipose tissues.

Simultaneous activation of GLP-1 and GIP receptors may result in synergistic and additive effects on glycemic control.

Combining therapies that target both GLP-1 and GIP receptors may improve treatment outcomes for diabetes.

A better healthcare provision for obesity treatment will initially burden the healthcare system but is expected to lead to a reduction in the obesity epidemic and cost savings in the long term.

Practitioners should prepare for initial challenges in the healthcare system while advocating for long-term benefits.

A broad societal consensus is crucial for implementing measures to reduce obesogenic living conditions.

Practitioners should engage with community efforts to create healthier environments.

Emerging clinical trials support the potential of GLP-1 receptor agonists in reversing cancer risk.

Practitioners should stay updated on clinical trial results regarding GLP-1 agonists and cancer risk.

Endoluminal metabolic and bariatric therapy may be an appealing option for patients ineligible for or averse to bariatric surgery.

Practitioners should consider these therapies for patients who cannot or do not want to undergo traditional surgery.

Recent advancements in anti-obesity drugs allow for genotype-informed treatment options.

Practitioners can utilize genetic information to tailor obesity treatments.

Dietary supplements are generally safe, but their regulation is less stringent than for medicines.

Practitioners should ensure patients are aware of the regulatory status of dietary supplements.

Future studies investigating the long-term effects of chronic high protein intake on bone tissue health are warranted.

Practitioners should consider the need for ongoing research into the long-term impacts of high protein diets on bone health.

A 10% energy surplus did not result in a significant change in body protein mass (0.00 kg; 95% CI, -0.38-0.39 kg; P = 0.980).

A modest increase in energy intake may not be sufficient to promote body protein mass gain.

Protein supplementation does not seem to provide further improvements in untrained and healthy subjects.

Practitioners should consider the training status of individuals when recommending protein supplementation.

Non-responders to the PF regimen demonstrated only transient and limited metabolic shifts.

Understanding the differences in metabolic responses can guide dietary strategies for T2D management.

A prescrição de suplementação alimentar nem sempre é realizada com orientação correta por profissionais adequados.

É crucial que a suplementação seja orientada por nutricionistas para evitar riscos à saúde.

Mitochondrial dysfunction plays a pivotal role in the onset and progression of diabetes.

Understanding mitochondrial dysfunction can guide therapeutic strategies for diabetes management.

Innovative therapeutic strategies are needed to address mitochondrial dysfunction in diabetes.

Practitioners should consider new therapies targeting mitochondrial function in diabetes care.

The prevalence of any remission in the plate model was 27.1% during the first 2 years, decreasing over time.

The plate model may initially improve diabetes remission rates, but these rates decline over time.

A shift towards reduced carbohydrate intake and increased dietary fat may be linked to higher morbidity and mortality rates in patients with diabetes.

Practitioners should consider the implications of dietary fat and carbohydrate ratios in diabetes management.

The majority of animal studies demonstrated a greater impact from high-fat diets compared with higher-sugar diets.

Animal studies suggest that high-fat diets may pose greater risks than high-sugar diets, informing dietary recommendations.

A plant-based diet is associated with an increased risk of higher TyG in women (OR = 1.25 for PDI and OR = 1.55 for hPDI).

Practitioners should be cautious about recommending high plant-based diets for women without considering overall dietary balance.